This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Incivek

Vertex Pharmaceuticals Incorporated

Drug Names(s): telaprevir, VX-950, LY570310, MP-424, Incivo (EU), Telavic (Japan)

Description: VX-950 targets the hepatitis C virus directly, by inhibiting the hepatitis C protease (NS3-4A).

Deal Structure: Vertex and Eli Lilly
In December 2001, Vertex and Eli Lilly selected VX-950 for preclinical development.

In January 2003, Vertex announced that it restructured its agreement with Eli Lilly and that Vertex will lead development and commercialization of VX-950. The mutual decision to restructure the agreement is a result of areprioritization of Eli Lilly's research portfolio and Vertex's desire tofocus on specialty pharmaceutical markets and retain greater downstream rights to its own compounds. In order to reflect these strategic priorities, the companies restructured their agreement. Vertex obtained the worldwide rights to compounds identified during the collaboration. Eli Lilly retains a financial interest in VX-950 and other HCV protease compounds through royalties on future net product sales. Financial terms of the restructuring were not disclosed. The royalty payment percentages to Eli Lilly are BioMedTracker estimates.

Mitsubishi Tanabe Pharma and...See full deal structure in Biomedtracker

Partners: Eli Lilly & Company Mitsubishi Tanabe Pharma Corporation Johnson & Johnson


Incivek News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug